{"schema_version":"1","generated_at":"2026-11-04T15:24:51.347Z","data_as_of":null,"url":"https://www.findmykol.com/kol/vijayakrishna-gadi","json_url":"https://www.findmykol.com/kol/vijayakrishna-gadi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"vijayakrishna-gadi","name":"Vijayakrishna Gadi","credential":"MD, PhD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Seattle","state":"WA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1053358671","orcid":"0000-0002-5427-7465","openalex":"A5073301255"},"summary":"Vijayakrishna Gadi is an Oncology physician. OpenAlex indexes 144 publications with 3,470 citations (h-index 32); ClinicalTrials.gov lists 4 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":144,"cited_by_count":3470,"h_index":32,"latest_activity_year":2025,"source":"works"},"trials":{"count":4,"shown":3,"withheld":1,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04891068","title":"BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"University of Illinois at Chicago","source_url":"https://clinicaltrials.gov/study/NCT04891068","trial_url":"https://www.findmykol.com/trial/NCT04891068"},{"nct":"NCT03238703","title":"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer","phase":"PHASE4","status":"WITHDRAWN","role":"Overall official","sponsor":"Fred Hutchinson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT03238703","trial_url":"https://www.findmykol.com/trial/NCT03238703"},{"nct":"NCT01816035","title":"Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"University of Washington","source_url":"https://clinicaltrials.gov/study/NCT01816035","trial_url":"https://www.findmykol.com/trial/NCT01816035"}],"source":"trials"},"payments":{"company_count":20,"program_years":{"first":2021,"last":null},"rows_total":48,"shown":3,"withheld":45,"rows":[{"payer":"Novartis","program_year":2025,"amount_usd":26560.72,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1053358671"},{"payer":"Gilead Sciences, Inc.","program_year":2025,"amount_usd":20340.21,"payment_count":27,"source_url":"https://openpaymentsdata.cms.gov/search?query=1053358671"},{"payer":"PUMA BIOTECHNOLOGY, INC.","program_year":2025,"amount_usd":16324.3,"payment_count":10,"source_url":"https://openpaymentsdata.cms.gov/search?query=1053358671"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1053358671","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":3,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":46.2,"drugs":[{"name":"Votrient","share_pct":100}],"max_beneficiaries":null},{"class":"Estrogen Agonist/Antagonist","setting":"prescribed","share_pct":30.8,"drugs":[{"name":"Tamoxifen Citrate","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2022,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02170","status":"verified"},{"title":"Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics","year":2023,"journal":"Clinical Breast Cancer","source_url":"https://doi.org/10.1016/j.clbc.2023.03.007","status":"verified"},{"title":"Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial","year":2022,"journal":"npj Breast Cancer","source_url":"https://doi.org/10.1038/s41523-022-00385-2","status":"verified"},{"title":"Preoperative Systemic Therapy for Breast Cancer","year":2022,"journal":"Surgical Clinics of North America","source_url":"https://doi.org/10.1016/j.suc.2022.08.017","status":"verified"},{"title":"Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer","year":2022,"journal":"Annals of Surgical Oncology","source_url":"https://doi.org/10.1245/s10434-022-12088-w","status":"verified"}],"source":"works"},"contact":{"address_1":"825 EASTLAKE AVE E","city":"Seattle","state":"WA","zip":"98109","phone":"206-228-1000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1053358671","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":1,"payments":45,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-03-05","provider_certified":"2025-03-05","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}